InsiderSignal.AI

InsiderSignal.ai

LENZ - Lenz Therapeutics, Inc.

Insider Purchase by Schimmelpennink Evert B. (Pres, CEO, Secretary)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

1 week ago, Schimmelpennink Evert B., serving as Pres, CEO, Secretary at Lenz Therapeutics, Inc. (LENZ), purchased 28,089 shares at $8.95 per share, for a total transaction value of $251,411.00. Following this transaction, Schimmelpennink Evert B. now holds 77,289 shares of LENZ.

This purchase represents a 57.00% increase in Schimmelpennink Evert B.'s stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Friday, March 27, 2026 and publicly disclosed via SEC Form 4 filing on Monday, March 30, 2026, 3 days after the trade was made.

Lenz Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Schimmelpennink Evert B.

Schimmelpennink Evert B.

Pres, CEO, Secretary

Evert B. Schimmelpennink, also known as Eef, is the President, Chief Executive Officer, Secretary, and Director of LENZ Therapeutics, Inc. (LENZ), a biopharmaceutical company focused on ophthalmic pharmaceuticals, a role he has held since March 2021.[[1]](https://ir.lenz-tx.com/company-information/executive-team)[[3]](https://www.marketscreener.com/insider/EVERT-SCHIMMELPENNINK-A2965R/)[[4]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/management) He recently engaged in insider trading at LENZ in this capacity.[user query context] Schimmelpennink brings extensive experience in biopharmaceutical leadership, having previously served as President and CEO of Pfenex, Inc. from 2017 to 2020 until its acquisition by Ligand Pharmaceuticals, and as CEO of Alvotech from 2015 to 2017.[[1]](https://ir.lenz-tx.com/company-information/executive-team)[[3]](https://www.marketscreener.com/insider/EVERT-SCHIMMELPENNINK-A2965R/) Earlier roles include senior positions at Pfizer Inc. as Vice President of Global Sterile Injectables, Hospira Inc. as Vice President of Global Generics, and Synthon BV as Vice President of Sales & Marketing.[[1]](https://ir.lenz-tx.com/company-information/executive-team)[[3]](https://www.marketscreener.com/insider/EVERT-SCHIMMELPENNINK-A2965R/) He currently chairs the board of Contineum Therapeutics, Inc. since 2022 and serves as an independent director at iBio, Inc. and Pipeline Therapeutics.[[3]](https://www.marketscreener.com/insider/EVERT-SCHIMMELPENNINK-A2965R/)[[4]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-lenz/lenz-therapeutics/management) Schimmelpennink holds an M.Sc. in Bioprocess Engineering from Wageningen University and a business degree from Arnhem Business School.[[1]](https://ir.lenz-tx.com/company-information/executive-team)

View full insider profile →

Trade Price

$8.95

Quantity

28,089

Total Value

$251,411.00

Shares Owned

77,289

Trade Date

Friday, March 27, 2026

9 days ago

SEC Filing Date

Monday, March 30, 2026

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Lenz Therapeutics, Inc.

Company Overview

No company information available
View news mentioning LENZ

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5217452

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime